利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

37572 records (took 0.055 seconds)

    Library of antigen-binding molecules including modified antibody variable region
    14.
    发明授权
    Library of antigen-binding molecules including modified antibody variable region 有权

    公开(公告)号：US12234573B2

    公开(公告)日：2025-02-25

    申请号：US17506733

    申请日：2021-10-21

    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA

    Inventor： Tomoyuki Igawa ,  Shojiro Kadono ,  Naoka Hironiwa ,  Mika Sakurai

    IPC: C40B40/10 ,  A61K39/395 ,  C07K16/28 ,  C07K16/42 ,  C12N15/09 ,  C40B30/04 ,  C40B40/08

    Abstract: The present inventors have successfully prepared a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, the antigen-binding molecules each comprising an antibody variable region that has binding activity against a first antigen and a second antigen different from the first antigen, but does not bind to the first antigen and the second antigen at the same time. Use of the library of the present invention allows the obtainment of a variable region having enhanced ability to bind to the first antigen and the production of a bispecific antibody against the first antigen and a cancer antigen. Moreover, the present inventors have also successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against three different antigens, but does not bind to these antigens at the same time.

    CD27 AGONISTS
    19.
    发明申请
    CD27 AGONISTS 有权

    公开(公告)号：US20250059291A1

    公开(公告)日：2025-02-20

    申请号：US18667334

    申请日：2024-05-17

    Applicant: Celldex Therapeutics, Inc.

    Inventor： Tibor KELER ,  Joel GOLDSTEIN ,  Lizhen HE ,  Henry C. MARSH ,  Karuna SUNDARAPANDIYAN ,  Lawrence J. THOMAS ,  Laura A. VITALE ,  Jenifer WIDGER

    IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  C07K14/705 ,  C07K16/30

    Abstract: The invention provides CD27 agonists comprising a first component that is an anti-CD27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an Fc receptor and the CD27 agonist stimulates T cell activity without the need for Fc receptor interaction. The cross-linking molecule(s) can be, for example, an anti-CD27, antibody, or antigen-binding fragment thereof, that can be the same or different than the first component. Alternatively, the cross-linking molecule(s) can be a CD27 ligand or a molecule (e.g., antibody) that binds a molecule on a cell such as a T cell, a tumor cell or a stromal cell. Pharmaceutical compositions comprising the CD27 agonists, and methods of using the CD27 agonists, are also provided.

Patent Agency Ranking